ABT Relative Valuation
ABT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ABT is overvalued; if below, it's undervalued.
Historical Valuation
Abbott Laboratories (ABT) is now in the Undervalued zone, suggesting that its current forward PE ratio of 22.65 is considered Undervalued compared with the five-year average of 24.63. The fair price of Abbott Laboratories (ABT) is between 139.73 to 159.32 according to relative valuation methord. Compared to the current price of 125.40 USD , Abbott Laboratories is Undervalued By 10.25%.
Relative Value
Fair Zone
139.73-159.32
Current Price：125.40
10.25%
Undervalued
22.65
PE
1Y
3Y
5Y
Trailing
Forward
17.42
EV/EBITDA
Abbott Laboratories. (ABT) has a current EV/EBITDA of 17.42. The 5-year average EV/EBITDA is 18.89. The thresholds are as follows: Strongly Undervalued below 16.20, Undervalued between 16.20 and 17.54, Fairly Valued between 20.23 and 17.54, Overvalued between 20.23 and 21.57, and Strongly Overvalued above 21.57. The current Forward EV/EBITDA of 17.42 falls within the Undervalued range.
19.86
EV/EBIT
Abbott Laboratories. (ABT) has a current EV/EBIT of 19.86. The 5-year average EV/EBIT is 21.69. The thresholds are as follows: Strongly Undervalued below 18.31, Undervalued between 18.31 and 20.00, Fairly Valued between 23.38 and 20.00, Overvalued between 23.38 and 25.07, and Strongly Overvalued above 25.07. The current Forward EV/EBIT of 19.86 falls within the Undervalued range.
4.61
PS
Abbott Laboratories. (ABT) has a current PS of 4.61. The 5-year average PS is 4.83. The thresholds are as follows: Strongly Undervalued below 3.99, Undervalued between 3.99 and 4.41, Fairly Valued between 5.26 and 4.41, Overvalued between 5.26 and 5.68, and Strongly Overvalued above 5.68. The current Forward PS of 4.61 falls within the Historic Trend Line -Fairly Valued range.
18.64
P/OCF
Abbott Laboratories. (ABT) has a current P/OCF of 18.64. The 5-year average P/OCF is 18.83. The thresholds are as follows: Strongly Undervalued below 13.17, Undervalued between 13.17 and 16.00, Fairly Valued between 21.66 and 16.00, Overvalued between 21.66 and 24.50, and Strongly Overvalued above 24.50. The current Forward P/OCF of 18.64 falls within the Historic Trend Line -Fairly Valued range.
23.69
P/FCF
Abbott Laboratories. (ABT) has a current P/FCF of 23.69. The 5-year average P/FCF is 22.90. The thresholds are as follows: Strongly Undervalued below 14.97, Undervalued between 14.97 and 18.94, Fairly Valued between 26.87 and 18.94, Overvalued between 26.87 and 30.83, and Strongly Overvalued above 30.83. The current Forward P/FCF of 23.69 falls within the Historic Trend Line -Fairly Valued range.
Abbott Laboratories (ABT) has a current Price-to-Book (P/B) ratio of 4.28. Compared to its 3-year average P/B ratio of 4.85 , the current P/B ratio is approximately -11.77% higher. Relative to its 5-year average P/B ratio of 5.30, the current P/B ratio is about -19.23% higher. Abbott Laboratories (ABT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 2.89%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 3.31% , the current FCF yield is about -100.00% lower.
4.28
P/B
Median3y
4.85
Median5y
5.30
3.17
FCF Yield
Median3y
2.89
Median5y
3.31
Competitors Valuation Multiple
The average P/S ratio for ABT's competitors is , providing a benchmark for relative valuation. Abbott Laboratories Corp (ABT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 6.90%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ABT increased by 10.87% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 14.25 to 15.75.
The secondary factor is the Revenue Growth, contributed 6.90%to the performance.
Overall, the performance of ABT in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Abbott Laboratories (ABT) currently overvalued or undervalued?
What is Abbott Laboratories (ABT) fair value?
How does ABT's valuation metrics compare to the industry average?
What is the current P/B ratio for Abbott Laboratories (ABT) as of Dec 05 2025?
What is the current FCF Yield for Abbott Laboratories (ABT) as of Dec 05 2025?
What is the current Forward P/E ratio for Abbott Laboratories (ABT) as of Dec 05 2025?